A Phase I Study of Bevacizumab and Intravenous Ascorbic Acid for Patients With Recurrent High Grade Glioma
Latest Information Update: 27 Oct 2023
At a glance
- Drugs Ascorbic acid (Primary) ; Bevacizumab (Primary)
- Indications Glioma
- Focus Adverse reactions
- 25 Jul 2019 Status changed from active, no longer recruiting to discontinued.
- 02 Aug 2018 Status changed from recruiting to active, no longer recruiting.
- 19 Jul 2016 New trial record